Exhibit 99

Seven Peer-Reviewed Journal Articles Further Validate CardioDynamics'
Clinical Application in Heart Failure

    SAN DIEGO--(BUSINESS WIRE)--April 6, 2004--

   ICG's Exposure Broadened Through Circulation to 18,000 Physicians

    CardioDynamics (Nasdaq: CDIC), the innovator and leader of
Impedance Cardiography (ICG) technology, today announced publication
of seven peer-reviewed articles in Congestive Heart Failure
March/April 2004 supplement. Prominent clinical cardiologists and
researchers contributed to further refine the important role of ICG in
clinical practice. Congestive Heart Failure, a peer-reviewed journal
with distribution to over 18,000 office and hospital-based
cardiologists and internists who treat cardiovascular disease,
dedicated an entire supplement to the Company's ICG technology. The
ICG supplement can be downloaded at www.lejacq.com/supplements.
    Contributors to the publication included Marc A. Silver, M.D.,
Clinical Professor and Chairman, Department of Medicine and Director
of the Heart Failure Institute, Christ Hospital and Medical Center,
Oak Lawn, IL; John E. Strobeck, M.D., Ph.D., Director, Heart-Lung
Center, Hawthorne, NJ; Kris Vijay, M.D., Director of Heart Failure and
Clinical Research, Arizona Heart Institute, Phoenix, AZ; Gordon L.
Yung, M.D., Medical Director, Lung Transplant Program, University of
California, San Diego, CA; Richard L. Summers, M.D., Professor and
Research Director, Emergency Department, University of Mississippi,
Jackson, MS; and Charles L. Springfield, M.D., Director of Emergency
Services, Aventura Hospital and Medical Center, Aventura, FL. Drs.
Silver and Strobeck are world-renown ICG experts and medical advisors
to the Company.
    The articles demonstrate ICG's accuracy compared to the direct
Fick and thermodilution methods of determining cardiac output; ability
to simply and cost-effectively identify changes in heart function
compared to echocardiography; utility in differentiating diagnosis of
patients with shortness of breath; ability to replace pulmonary artery
catheterization, which has tremendous cost implications for hospitals;
and prognostic role of changes in ICG parameters in patients with
chronic heart failure.
    In the Journal's editorial Beyond the Four Quadrants: The Critical
and Emerging Role of Impedance Cardiography in Heart Failure, the
editors discussed the cost-effective and clinical value of ICG and
highlighted, "The direct cost of treating heart failure is estimated
to be $56 billion per year in the United States and the number of
heart failure patients in this country may reach 10 million people by
2010. A significant portion of the cost of heart failure care is the
high cost of hospitalizations for patients with acute decompensation.
Through careful surveillance of patients with chronic heart failure
using improved methods for measuring hemodynamic and neurohormonal
status, primary care physicians and cardiologists may be able to
intervene in a timely manner and prevent acute episodes leading to
hospitalization, major morbidity, or death."
    "This company-sponsored publication adds to the growing body of
literature supporting the accuracy, clinical value, and significant
cost-saving benefits of our technology, and further educates
clinicians on ICG's diagnostic, prognostic and treatment value,"
stated Michael K. Perry, Chief Executive Officer of CardioDynamics.
"Our ICG technology provides physicians with important objective
information they need to assess, diagnose, and aggressively treat
cardiovascular disease, an epidemic that claims more lives than all
cancers combined and costs the U.S. an estimated $368 billion each
year. The Congestive Heart Failure publication helps further define
the valuable role of our noninvasive technology in decreasing these
costs and improving quality of life."

    About CardioDynamics:

    CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator
and leader of breakthrough medical technology called Impedance
Cardiography (ICG). The Company's BioZ Systems are being used by
leading physicians around the world to help battle the number one
killer of men and women - cardiovascular disease. Partners include GE
Medical Systems Information Technologies and Philips Medical Systems.
The worldwide market potential for BioZ products is estimated to be $5
billion and an additional $800 million in recurring annual revenue for
sensors. For additional information or to request an investor package,
please refer to the company's Web site at www.cdic.com.

    Forward-Looking (Safe Harbor) Statement:

    Except for the historical and factual information contained
herein, this press release contains forward-looking statements, such
as market size, potential, growth and penetration rates, the accuracy
of which is necessarily subject to uncertainties and risks including
the Company's sole dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as
other risks detailed in the Company's filings with the SEC, including
its 2003 Form 10-K. The Company does not undertake to update the
disclosures contained in this press release.

    CONTACT: CardioDynamics
             Bonnie Ortega, Investor Relations
             800-778-4825, Ext. 1005
             bonnie@cdic.com
             Irene Paigah, Media Relations
             800-778-4825, Ext. 1012
             ip@cdic.com